TransMedics Group (NASDAQ: TMDX)
TransMedics Group Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
TransMedics Group Company Info
TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.
News & Analysis
TransMedics Group Stock: A Millionaire-Maker in the Making?
1 Compelling Reason to Buy and Hold TransMedics Group Stock Forever
1 Turnaround Growth Stock Down 60% That Could Double, According to Wall Street
Down 62%. Should You Buy TransMedics Stock on the Dip?
TransMedics' Revenue Surged 49.8% in Q4
The organ transplant technology specialist significantly exceeded Wall Street's estimates in the fourth quarter.
Why TransMedics Fell 15.7% This Week
Investing in the Best Healthcare Stocks
TransMedics Stock Is Worth $0 According to This Short-Seller. Here's Why I'm Not Selling.
Valuation
Earnings Transcripts
TransMedics Group, Inc. (TMDX) Q3 2020 Earnings Call Transcript
TMDX earnings call for the period ending September 30, 2020.
TransMedics Group, Inc. (TMDX) Q2 2020 Earnings Call Transcript
TMDX earnings call for the period ending June 30, 2020.
TransMedics Group, Inc. (TMDX) Q1 2020 Earnings Call Transcript
TMDX earnings call for the period ending March 31, 2020.
TransMedics Group, Inc. (TMDX) Q4 2019 Earnings Call Transcript
TMDX earnings call for the period ending December 28, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.